Literature DB >> 15031640

Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

D M C Brinkman1, C M Jol-van der Zijde, M M ten Dam, J M Vossen, A D M E Osterhaus, F P Kroon, M J D van Tol.   

Abstract

We investigated the humoral (antigen-specific immunoglobulin isotypes, IgG subclasses, and avidity maturation) and cellular (antigen-specific in vitro proliferation) immune response in 18 healthy adult volunteers, following a primary and a single booster vaccination with the T-cell dependent neoantigen rabies administered at a 3-months interval. The IgG antibody titer showed a mean 31-fold increase (range 3-154) 4 weeks after the first vaccination and a memory response was observed after booster vaccination, i.e. high IgG titers, switch from IgM to IgG and IgA and increased antibody avidity. All healthy adults showed a rabies-induced proliferative response with a mean stimulation index of 45 (range 3.5-200) after in vitro stimulation of PBMC obtained at 4 weeks after booster vaccination. The results obtained in this study provide a frame of reference for the interpretation of specific immune responses to the T-cell dependent neoantigen rabies in patients suspected of a primary or secondary immunodeficiency. Humoral and cellular immune responses to the rabies neoantigen provide complementary information on the condition of the immune system of an individual. Five patients diagnosed with a combined immunodeficiency were vaccinated using the same protocol and showed a number of abnormalities, either in the humoral or the cellular immune response to the rabies neoantigen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15031640     DOI: 10.1023/b:joci.0000010429.36461.6b

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  46 in total

1.  Common variable immunodeficiency: clinical and immunological features of 248 patients.

Authors:  C Cunningham-Rundles; C Bodian
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

2.  Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen.

Authors:  G Ghaffari; D J Passalacqua; B S Bender; D J Briggs; M M Goodenow; J W Sleasman
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

3.  Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination.

Authors:  L Bracci; S K Ballas; A Spreafico; P Neri
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

4.  Clonal analysis of a human antibody response. III. Nucleotide sequences of monoclonal IgM, IgG, and IgA to rabies virus reveal restricted V kappa gene utilization, junctional V kappa J kappa and V lambda J lambda diversity, and somatic hypermutation.

Authors:  W Ikematsu; J Kobarg; H Ikematsu; Y Ichiyoshi; P Casali
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

5.  Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults.

Authors:  D J Briggs; D W Dreesen; P Morgan; J E Chin; C D Seedle; L Cryz; R Glück; S J Cryz
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

6.  Antibody avidity determination by ELISA using thiocyanate elution.

Authors:  G R Pullen; M G Fitzgerald; C S Hosking
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

7.  Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis.

Authors:  R W Luxton; E J Thompson
Journal:  J Immunol Methods       Date:  1990-08-07       Impact factor: 2.303

8.  Quantitative assay and potency test of antirabies serum and immunoglobulin.

Authors:  P Atanasiu
Journal:  Monogr Ser World Health Organ       Date:  1973

9.  Evidence for a viral superantigen in humans.

Authors:  M Lafon; M Lafage; A Martinez-Arends; R Ramirez; F Vuillier; D Charron; V Lotteau; D Scott-Algara
Journal:  Nature       Date:  1992-08-06       Impact factor: 49.962

10.  Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants.

Authors:  S Chutivongse; H Wilde; M Benjavongkulchai; P Chomchey; S Punthawong
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

View more
  12 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Recombinant outer membrane protein C of Aeromonas hydrophila elicits mixed immune response and generates agglutinating antibodies.

Authors:  Sunita Kumari Yadav; Jitendra Kumar Meena; Mahima Sharma; Aparna Dixit
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  Modeling human adaptive immune responses with tonsil organoids.

Authors:  Lisa E Wagar; Ameen Salahudeen; Christian M Constantz; Ben S Wendel; Michael M Lyons; Vamsee Mallajosyula; Lauren P Jatt; Julia Z Adamska; Lisa K Blum; Neha Gupta; Katherine J L Jackson; Fan Yang; Katharina Röltgen; Krishna M Roskin; Kelly M Blaine; Kara D Meister; Iram N Ahmad; Mario Cortese; Emery G Dora; Sean N Tucker; Anne I Sperling; Aarti Jain; D Huw Davies; Philip L Felgner; Gregory B Hammer; Peter S Kim; William H Robinson; Scott D Boyd; Calvin J Kuo; Mark M Davis
Journal:  Nat Med       Date:  2021-01-11       Impact factor: 53.440

4.  CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

Authors:  Joris M van Montfrans; Andy I M Hoepelman; Sigrid Otto; Marielle van Gijn; Lisette van de Corput; Roel A de Weger; Linda Monaco-Shawver; Pinaki P Banerjee; Elisabeth A M Sanders; Cornelia M Jol-van der Zijde; Michael R Betts; Jordan S Orange; Andries C Bloem; Kiki Tesselaar
Journal:  J Allergy Clin Immunol       Date:  2011-12-24       Impact factor: 10.793

Review 5.  New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

Authors:  R Ameratunga; S-T Woon; D Gillis; W Koopmans; R Steele
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

Authors:  Livio Azzoni; Andrea S Foulkes; Cynthia Firnhaber; Xiangfan Yin; Zhi Q Xiang; Yan Li; Wendy Stevens; Robert Gross; Hildegund C J Ertl; Ian Sanne; Luis J Montaner
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

7.  Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

Authors:  Dominic F Kelly; Matthew D Snape; Kirsten P Perrett; Elizabeth A Clutterbuck; Susan Lewis; Geraldine Blanchard Rohner; Meryl Jones; Ly-Mee Yu; Andrew J Pollard
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

8.  Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans.

Authors:  Geraldine Blanchard-Rohner; Anoop S Pulickal; Cornelia M Jol-van der Zijde; Matthew D Snape; Andrew J Pollard
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

9.  Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; P A W te Boekhorst; R ten Cate; N M Wulffraat; R Q Hintzen; J M Vossen; M J D van Tol
Journal:  J Clin Immunol       Date:  2007-08-10       Impact factor: 8.317

10.  Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis.

Authors:  Nina M van Leeuwen; Maaike Boonstra; Jaap A Bakker; Annette Grummels; Suzana Jordan; Sophie Liem; Oliver Distler; Anna-Maria Hoffmann-Vold; Karin Melsens; Vanessa Smith; Marie-Elise Truchetet; Hans U Scherer; René Toes; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2021-11-02       Impact factor: 15.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.